ImmuCell Corporation

Good morning and welcome to the ME Cell Corporation Report's third quarter ended September 30th, 2025, unaudited financial results conference call. All participants will be in listen-only mode. After today's presentation, there will be an opportunity to ask questions. Please note this event is being recorded. I would now like to turn the conference over to Joe Diaz of Blitzen Partners. Please go ahead.

Thank you, Rocco. Good morning and welcome to everyone. As Rocco indicated, my name is Joe Diaz with Lethem Partners. We're the investor relations consulting firm for Emucel. I want to thank all of you for joining us today to discuss the unaudited financial results for the third quarter ended September 30, 2025. Listeners are cautioned that statements made by management during the course of this call include forward-looking statements, which include any statements that refer to the future events or expected future results or predictions about steps the company plans to take in the future. These statements are not guarantees of performance and are subject to risks and uncertainties that could cause actual results, outcomes, or events to differ materially from those discussed today. Additional information regarding forward-looking statements and the risks and uncertainties that could impact future results, outcomes, or events is available under the cautionary note regarding forward-looking statements, better known as a safe harbor statement provided with the Form 10-Q and the press release that the company filed last night, along with the company's other periodic filings with the SEC. Information discussed on today's call speaks only as of today, Friday, November 14, 2025. The company undertakes no obligation to update any information discussed on today's call. Please note that references to certain non-GAAP financial measures may be made during today's call. The company included definitions of these terms as well as reconciliations of these figures to the most comparable GAAP financial measures. in last night's press release in order to better assist you in understanding its financial performance. With that said, let me turn the call over to Michael Brigham, Special Advisor to the CEO of Emicell Corporation, for opening remarks. Michael.

Hey, thanks, Joe, and good morning, everyone. This is an exciting time in Emicell. Lots of good change going on. Our financial performance over the first nine months of 2025 is greatly improved compared to prior year, a turnaround which was made possible in part by increasing our production output while improving gross margins. We are now in a great position as a company with a stock distribution channel and an energized commercial team. Our CEO and CFO will be commenting on the financial results in greater detail in just a moment. On another topic of change, we are amidst two very positive management transitions right now at Emusel. First, as most of you know by now, we added Timothy Fiore, our CFO, to the team back in April. Secondly, back in June, we announced a CEO succession plan. This effort was completed successfully, effective November 1st, 2025, with the hiring of Oliver Taboukos as our new president and CEO. I'd like to welcome Oliver to the company. Oliver brings over 25 years of leadership and results-focused execution experience in animal health to Imicel. Before joining Imicel, he served as an operating partner of Archimed, a global healthcare investment firm where he focused on animal health investments and served as chairman and chief executive officer of a portfolio company. Prior to that, Mr. Taboukours Was at IDEX for 18 years. IDEX is a Maine-based NASDAQ-listed company with more than $4 billion in revenue. We're all over lead strategy and M&A activities from 2004 to 2008, and then served as a corporate officer, senior vice president, and general manager of several business units from 2008 to 2021, including their livestock and dairy antibiotic residue testing businesses. He has a track record of driving growth and operational excellence in the livestock industry, and as I step away in January after 36 years with Emucel, I am very confident that we are in good hands with Oliver and Tim. At this point, I will turn the call over to Oliver for a few comments. Oliver.